Non-alcoholic steatohepatitis (NASH) is associated with many clinical characteristics including Type 2 diabetes mellitus and obesity which collectively termed as metabolic syndrome or the insulin resistance syndrome. Adiponectin is an adipokines which help to prevent the development of NASH and cirrhosis. Pioglitazone therapy is associated with improvements in steatosis, parenchymal inflammation, cell injury, and fibrosis. Adiponectin level in plasma are increased by pioglitazone treatment that improves steatosis and necroinflammation.
Loading....